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Mondia whitei (Apocynaceae) is used in traditional medicine to treat nervous disorders. Previous studies have shown in vivo antidepressant-
like activity in the forced swimming test and affinity to the serotonin transporter of an ethanolic leaf extract ofM. whitei. The aim of this study was
to isolate the compound(s) responsible for in-vitro serotonin transporter affinity inM. whitei. Bioassay guided isolation lead to the identification of
the monoterpene lactone (−)-loliolide. An ethanol extract was prepared from dry leaves. The residue was dissolved in ethyl acetate, extracted with
water by liquid–liquid partitioning. This was followed by VLC fractionation. Through HPLC-UV separation the active compound was isolated
and characterized by GC-MS, LC-MS and 1H-NMR. The activity of (−)-loliolide was tested in a serotonin transporter binding assay using [3H]-
citalopram as ligand, giving an IC50-value of 997 µM, corresponding to a Ki-value of 409 µM. Loliolide is a non-nitrogenous compound and
might bind to the transporter in a different way to nitrogen-containing inhibitors. The results provide a rationale for the use of M. whitei in the
treatment of depression and other central nervous system diseases in traditional medicine.
© 2010 SAAB. Published by Elsevier B.V. All rights reserved.Keywords: [3H]-citalopram; Depression; Loliolide; Mondia whitei; Radioligand binding assay; Serotonin transporter1. Introduction
Depression is an ailment that is highly disabling. It is
estimated that depression at one time or another will affect 25%
of the world population (WHO, 2001). In southern Africa, a
place traumatized by civil wars, political transition and AIDS,
depressive disorders are common. The western health care
system in southern Africa is overburdened, so patients are often
relying on traditional medicine. However, African traditional
healers do not recognize depression as an illness, though a
number of other states and conditions with symptoms similar to
depression are known, for example the condition ‘being put
down’ by the ancestors (Stafford et al., 2008). Persons inflicted
with curses and evil spirits often have symptoms that resemble a
depressed state accompanied by lethargy. The incongruence
between indigenous and western disease nomenclature makes it⁎ Corresponding author. Tel.: +45 35336339; fax: +45 35336041.
E-mail address: ankj@farma.ku.dk (A.K. Jäger).
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doi:10.1016/j.sajb.2010.02.091more difficult to evaluate the use of plants in a western scientific
paradigm.
In a screening programme of plants used for depression-like
disorders in traditional medicine in South Africa, an ethanolic
extract of Mondia whitei leaves showed affinity to the serotonin
transporter (SERT) (Nielsen et al., 2004). An ethanolic leaf
extract of M. whitei was tested for affinity to the serotonin-,
noradrenalin- and dopamine transporters in COS7 cells trans-
fected with human transporters. TheM. whitei extract had affinity
to the serotonin transporter, but not to the noradrenaline or
dopamine transporters (Pedersen et al., 2008). Further studies in
rats showed that ethanolic extracts had activity in a forced
swimming test indicating a possible antidepressant-like effect
(Pedersen et al., 2008). These in vivo results also indicate that the
active constituents are able to pass the blood brain barrier.
M. whitei is a robust forest climber, which has been used in
African traditional medicine for centuries. Mainly the roots are
used in medical treatment but the leaves and the entire plant has
been utilized as well. The roots have a pleasant aromaticts reserved.
Fig. 1. Displacement of citalopram by VLC and HPLC fractions; and
determination of IC50-value for loliolide in the serotonin transporter assay.
594 J.S. Neergaard et al. / South African Journal of Botany 76 (2010) 593–596character and taste not unlike cinnamon and vanilla. Through-
out Africa the dried roots are chewed and the sap swallowed as
an aphrodisiac (Neuwinger, 2000). Root bark is used in
Zimbabwe in a preparation known as vuka-vuka (Shona,
which translates as wake-up, wake-up), which is reported to
be a ‘natural viagra’, and is used as a male sexual stimulant
(Hostettmann et al., 2000). In South Africa, the Zulu call it
uMondi from which the genus gets its name. The roots are used
in tonics, as an appetite stimulant, against abdominal pains,
constipation and in the treatment of heartburn (Watt and Breyer-
Brandwijk, 1962; Hutchings et al., 1996). Root extracts have
shown an androgenic effect in male rats (Watcho et al., 2004).
Decoctions of the leaves are used as antispasmodics in pregnant
women (Koorbanally et al., 2000). Water extracts yielded a very
low toxicity (Watcho et al., 2004).
Despite its long and extensive use, there have been only a
few studies on the isolation of bioactive compounds from M.
whitei. A potent tyrosinase inhibitor, 2-hydroxy-4-methoxy-
benzaldehyde, along with three chlorinated coumarinolignans
have been isolated from the roots (Kubo and Kinst-Hori, 1999;
Patnam et al., 2005).
Based on the in vivo activity and transporter selectivity, we
decided to carry out a bioassay-guided isolation of the
compound in M. whitei leaves with affinity to the SERT.
2. Materials and methods
2.1. Plant material
Leaves of M. whitei (Hook. f.) Skeels (Apocynaceae) were
collected at the botanical garden at the University of KwaZulu-
Natal, Pietermaritzburg (29°37′29S 30°24′15E Alt: 600 m)
KwaZulu-Natal, South Africa. G. I. Stafford authenticated the
plant material. A voucher specimen (Stafford 43 NU) was
deposited in the Bews Herbarium (NU), University of KwaZulu-
Natal, Pietermaritzburg.
2.2. Extraction
Fifty grams of ground dryM.whitei leaveswere extracted with
absolute ethanol (3×500 ml). During each extraction the plant
material was sonicated for 60 min. The extract was evaporated to
dryness in vacuo and the residue dissolved in 200 ml ethyl acetate.
The solution was partitioned against 3×200 ml Milli-Q water.
The ethyl acetate phase was evaporated to dryness (1.45 g).
2.3. Bioassay-guided fractionation and isolation
2.3.1. Vacuum liquid chromatography
The extract was dissolved in 100 ml ethyl acetate. To the
solutionwas added 15 g celite and residual water was removed by
co-evaporation with 50 ml heptane. The sample on celite was
fractionated on Silicagel 60 (0.015–0.040 mm) on a 40×150 mm
column. Two hundred ml of each of the following solvents were
used as eluents: Toluene; toluene:ethyl acetate 80:20; 50:50;
20:80 (4×50 ml); ethyl acetate (4×50 ml); ethyl acetate:ethanol
80:20 (4×50 ml). Finally the column was eluted with 5×50 mlmethanol. The fractions were tested in the SERT binding assay
(Fig. 1). One of the active fractions from VLC (toluene:ethyl
acetate 20:80) was further purified by preparative HPLC.
2.3.2. Preparative HPLC
Preparative HPLC was carried out on a Waters 1525 Binary
HPLC Pump, connected to a Waters 2996 Photodiode Array
Detector. A Luna-C18 column was used (250×21.2 mm, 5 µm,
Phenomenex) eluted with a mixture of acetonitrile and Milli-Q
water. The eluent composition was A: 100% Milli-Q water and
B: 100% acetonitrile. The column was eluted with a linear
gradient (A:B) from 100:0 (T0) to 0:100 (T30) to 0:100 (T60) at a
flow-rate of 10.0 ml/min. Samples (450 µl) were filtered
through a 0.45 µM filter before each injection. Five fractions
Fig. 2. Structure of (−)-loliolide showing important HMBC and NOESY
correlations.
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active fraction (II: 20.9–24.2 min) (Fig. 1) analyzed by 1H-NMR
(Varian Mercury Plus 300 MHz; CDCl3), GC-MS and LC-MS.
Optical rotation was determined on a Perkin-Elmer 241
polarimeter.
2.3.3. [3H]-Citalopram binding assay
Themethod described by Plenge et al. (1990) andNielsen et al.
(2004) was used with modifications. Briefly, whole rat brains,
except cerebellum, were homogenized with an Ultra Turax
homogenizer in 1:10 (w/v) buffer 1 (TRIS base 5 mM; NaCl
150 mM; EDTA 20 mM; pH 7.5). The homogenate was
centrifuged at 14,000 g for 10 min and the homogenized tissue
pellet washed with the same buffer 1:10 (w/v). The supernatant
was discarded; the pellet was suspended in buffer 2 (TRIS base
5 mM; EDTA 5 mM; pH 7.5), left to react for 20 min at 0 °C and
centrifuged at 14,000 g for 10 min. The supernatant was
discarded and the pellet was suspended in buffer 3 (TRIS base
50 mM; NaCl 120 mM; KCl 5 mM; pH 7.5) and centrifuged at
14,000 g for 10 min. The supernatant was discarded and the
protein pellet finally suspended in 1:10 (w/v) buffer 4 (TRIS base
500 mM; NaCl 1200 mM; KCl 50 mM; pH 7.5). The tissue
homogenate was kept at −70 °C until use.
The compound was tested at five concentrations from 10 mg/
ml (0.83 mg/ml in the assay) to 0.01 mg/ml (8.33·10−4 mg/ml in
the assay). Twenty-five µl of each dilution were mixed with 50 µl
of [3H]-citalopram (4 nM, 0.67 nM in the assay) and 225 µl of
tissue suspension, respectively. The total binding of [3H]-
citalopram was determined in assay buffer. Paroxetin (120 µM,
10 µM in the assay) was used for the determination of non-
specific binding. All samples were incubated for 2 h at 25 °C and
filtered under vacuum using Avantec GC50-25 mm glass fibre
filters. The radioactivity on the filters was determined by liquid
scintillation using Ultimo Gold XR as scintillation fluid. Specific
binding was calculated as total binding minus unspecific binding.
All experiments were done in triplicate.
2.3.4. Loliolide
The structure elucidation was done by comparison of both 1D
and 2D NMR data with those previously reported (Hiraga et al.,
1997; Kimura and Maki, 2002). The NOESY correlation helped
to define the relative stereochemistry and was consistent with
loliolide and not the diastereomer epiloliolide. The HMBC and
NOESY correlations are shown in Fig. 2.
3. Results and discussion
The monoterpene-lactone (−)-loliolide (Fig. 2) was isolated
from the leaves of M. whitei. During the bioassay-guided
isolation, fractions containing (−)-loliolide showed good dis-
placement of [3H]-citalopram from the SERT. The IC50 value in
the SERT assay was determined from the dose–response curve to
be 977 µM, giving a Ki-value of 409 µM (Fig. 1). The activity of
the compound is significantly lower than the activity of
citalopram with an IC50 value of 1.3 nM (Ki=0.6 nM).
In previous studies extracts of M. whitei have shown affinity
to SERT in a binding assay similar to the one used in this study(Nielsen et al., 2004). Ethanolic extracts have exhibited activity
both in the SERT binding assay, a functional SERT inhibition
assay utilizing COS-7 cells expressing hSERT, and had an
antidepressant-like effect in animal models (Pedersen et al.,
2008). This is the first time (−)-loliolide has been isolated from
leaves of M. whitei. It was first isolated from Lolium perenne
(Hodges and Porte, 1964). Loliolide has been isolated from a
number of higher plants and marine algae (Ghosal et al., 1976;
Pettit et al., 1980; Tanaka and Matsunaga, 1989; Kimura and
Maki, 2002). Loliolide is known to have immunosuppressive
and ant-repellent activities (Okunade and Wiemer 1985; Okada
et al., 1994). This compound accounts for some of the
antidepressant-like activity shown by the M. whitei extracts.
Without exception all antidepressant drugs showing SERT
inhibitory activity contain an amine nitrogen atom. These drugs
also share another structural feature in that they contain an
aromatic ring. Non-nitrogenous compounds have been tested
for their SERT blocking effect. The results suggest that non-
amine analogs of tropanes bind to, and block, SERT with
potencies comparable to conventional antidepressant drugs
(Goulet et al., 2001). (−)-Loliolide shares none of the mentioned
structural features of antidepressant drugs and further investiga-
tions of functional SERT inhibition activity and in vivo model
effects could be interesting.
4. Conclusions
Bioassay-guided fractionation resulted in the isolation of the
monoterpene–lactone loliolide, which has affinity to SERT. As
a non-nitrogenous compound, loliolide might bind to SERT in a
different way than standard nitrogen-containing serotonin
reuptake inhibitors. The results provide a rationale for the use
ofM. whitei against different central nervous system diseases in
traditional medicine.
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